Cytovance® Biologics Wins 2017 CMO Leadership Awards

Oklahoma City, OK – (March 14, 2017)Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories; Quality, Reliability and Compatibly, which will be given at the CMO Leadership Awards Ceremony to be held March 22, 2017, at the W Hotel in New York City, NY.

“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science leader magazine and “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development.  An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”

“We are honored to be awarded as a leader in the categories of Quality, Reliability and Compatibly by our clients in the CDMO marketplace,” stated Darren Head, President and CEO of Cytovance.  “Cytovance Biologics proudly employs a highly experienced team, and we remain ever-cognizant of the significance of providing unparalleled service to our clients. We accept this award as a testament of the dedication and hard work of many within our remarkable company."

About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.